Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
X-ray repair cross-complementing protein 5 (XRCC5), commonly called Ku80, is a core component of the non-homologous end joining (NHEJ) DNA double-strand break repair machinery. It forms a heterodimer with Ku70 (XRCC6) to create the Ku complex, which binds to DNA double-strand break ends, initiates recruitment of other repair factors, and is crucial for maintaining genome stability. XRCC5's functions include DNA end binding, assembly of the DNA-dependent protein kinase (DNA-PK) complex, and end-processing activities required for effective repair and V(D)J recombination in immune cells. XRCC5/Ku80 also plays roles in transcriptional regulation, ribosomal RNA processing, and innate immune response. Deregulation or mutation in XRCC5 is associated with increased cancer risk, immunodeficiency, radiosensitivity, and autoimmune phenomena[1][2][3][4][5][6][7].
Drug candidates working at this target generally act by inhibiting DNA-dependent protein kinase (DNA-PK) activity, leading to impaired NHEJ DNA repair and sensitization to DNA-damaging agents (e.g., ionizing radiation, chemotherapy)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-ray repair cross-complementing protein 5 (XRCC5).